Introduction
Invasive fungal disease represents a major threat to life in immunocompromised patients and is now one of the most common causes of infection in this group 1-4 with incidences from 5% to more than 20% in high risk groups. [5] [6] [7] In this patient group, it is essential that effective antifungal agents be administered rapidly. There is a limited range of antifungal agents available to treat disease caused by Aspergillus or Candida, including the polyenes, flucytosine, azoles and more recently the echinocandins. A variety of techniques have been recommended for the susceptibility testing of fungi to antifungal agents with NCCLS M38-A 8 and NCCLS M27-A2 9 widely accepted as the reference methods even though there are problems correlating the in vitro response with the in vivo outcome particularly for amphotericin B 10 against Aspergillus and the azoles against Candida. 11 Many other methods have been suggested including Etest 12,13 and disc diffusion but all these methods have the common feature that the in vitro activity is tested in air or air supplemented with 5% CO 2 .
It has been recognized for many years that even though atmospheric air contains approximately 21% O 2 (pO 2 is 19.7 kPa at sea level), the level in the alveoli of healthy lungs is nearer to 14% (pO 2 is 13.2 kPa). Despite an arterial pO 2 of 13.2 kPa, in actuality the available oxygen is nearer to 7.9 kPa due to the high affinity of haemoglobin for oxygen. By the time oxygen has reached the capillaries and diffused into the tissues its availability is much lower with levels of 2-4% (2-4 kPa) being common (pO 2 may be as low as 0.13 kPa owing to the tension gradient and distance from the capillary). 14 At the same time as the available O 2 decreases, a corresponding increase in CO 2 occurs with normal levels in venous blood near to 5.3 kPa.
Additionally it is clear that the available O 2 within abscesses and infected wounds is lower than the surrounding tissue 15,16 resulting in extremely hypoxic conditions. The situation within aspergillomas or infarcted lung tissue is unknown but other infarcted tissues such as brain have extremely hypoxic tissue conditions. Further it has previously been noted that the activity of the aminoglycosides is suppressed under low oxygen conditions similar to those likely to occur in infected tissues 17 with 10-fold increases in the MIC. During investigations of amphotericin B-induced damage and killing of Candida 
Materials and methods

Organisms and preparation of inoculum
Susceptibility tests were carried out on 37 isolates of Aspergillus belonging to four different species and 24 isolates of Candida belonging to six species; all were recent clinical isolates from a variety of patient types. The group comprised 20 A. fumigatus, seven A. terreus, four A. flavus, six A. niger, five C. albicans, five C. tropicalis, four C. parapsilosis, four C. guilliermondii, three C. glabrata and three C. krusei. C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were tested with each set of experiments to ensure quality control. 9 The isolates were subcultured from frozen stock and were grown on Sabouraud dextrose agar (Difco, Surrey, UK) at 37°C in air for up to 10 days. Aspergillus conidia were harvested by washing the surface of the culture with 25 mL of phosphate buffered saline (Life Technologies, Paisley, UK) plus 0.05% Tween 80 (Sigma, Poole, UK) (PBST). Candida blastoconidia from three or four colonies were collected and suspended in PBST. The conidia and blastoconidia were counted using a haemocytometer and diluted as required in PBST.
Antifungal agents
ITC was obtained from Janssen-Cilag Ltd (High Wycombe, UK), AMB was obtained from Sigma (Poole, Dorset, UK) and MICA was provided by Fujisawa (Osaka, Japan).
ITC was first dissolved in acetone (Sigma) and then 0.2 M hydrochloric acid (Sigma) was added to provide a stock solution of 3200 mg/L. AMB was dissolved in dimethyl sulphoxide (Sigma), to provide a stock solution of 3200 mg/L (after adjusting for potency).
MICA powder was dissolved in 5% glucose (in water), to produce a stock solution of 1280 mg/L.
All drug stocks after preparation were dispensed into aliquots and stored in glass vials, protected from the light, at -70°C until required.
Susceptibility testing
Microdilution susceptibility tests for AMB, ITC and MICA were carried out as recommended by the NCCLS M38-A or M27-A2 using RPMI 1640 (Sigma) buffered with MOPS (Melford Laboratories Ltd, Ipswich, Suffolk, UK) to pH 7.0, the medium was modified by the addition of 2% glucose (Sigma). 20 Final drug concentrations used for ITC and AMB were 0.008-8 mg/L and for MICA 0.004-4 mg/L (a subgroup of Aspergillus isolates were tested at MICA concentrations of 0.000125-4 mg/L); all drug dilutions were made in RPMI 1640. Final inocula were 0.5-5 × 10 4 conidia/mL (Aspergillus) and 0.5-2.5 × 10 3 blastoconidia/mL (Candida). All microdilution plates were prepared in triplicate (on at least two occasions for Aspergillus and three occasions for Candida) and incubated in different atmospheres. Plates were incubated at 37°C for 48 h.
Minimum inhibitory concentrations (MICs) for Aspergillus were read visually with a no growth endpoint for AMB and ITC. For MICA, plates were examined using oblique lighting; the first well in which there was a prominent reduction in growth was taken as the MIC. MICs for Candida were read spectrophotometrically (at 490 nm) with an 80% reduction in growth endpoint for ITC and a no growth endpoint for AMB and MICA.
Minimum fungicidal concentrations (MFCs) were determined by culturing 100 µL from each well in the microdilution plate that had no visible growth; the MFC was taken as the first well with less than 5 cfu (99.99% kill for Aspergillus and a 99% kill for Candida).
Gas mixtures in incubation atmosphere
During incubation, the microdilution plates were sealed in gas-tight jars and gas flow was maintained over the plates at a steady rate of 0.25 bar above atmospheric pressure.
Three different gas mixtures were used to generate the incubation atmosphere in the study (BOC Special Gases, Manchester, UK): (i) 20% oxygen/5% carbon dioxide/75% nitrogen; (ii) 1% oxygen/5% carbon dioxide/94% nitrogen; (iii) 0.25% oxygen/5% carbon dioxide/94.75% nitrogen.
Statistical analysis
Data were analysed by the Kruskal-Wallis test (pairwise comparison Conover-Inman) using the computer package StatsDirect (Ashwell, UK). Box plots were generated using the computer package Analyse-It (Leeds, UK).
For data analysis, MICs and MFCs of >8 mg/L were recorded as 16 mg/L.
Results
Summaries of the in vitro susceptibility tests of Aspergillus are presented in Table 1 and Combined data from all the Aspergillus species for AMB demonstrated a stepwise reduction in the MIC indicating that strains were more susceptible (as measured by MIC) in hypoxic conditions (P = 0.03 for 20% versus 1% and P < 0.0001 for 20% versus 0.25%). This trend could be seen in Aspergillus species but some comparisons did not reach statistical significance (this trend is clear in Figure 1 Data for MICA MICs did not demonstrate a trend with increasing hypoxia with all MICs being ≤0.004 mg/L in all conditions. The subgroup of the Aspergillus isolates retested at MICA concentrations lower than 0.004 mg/L demonstrated a trend towards increased susceptibility when oxygen was reduced to 1% (this was not further increased on reduction of oxygen to 0.25%). Assigning an MIC to the susceptibility in air was difficult because of the high level of residual growth. Furthermore, MICA was not fungicidal against any Aspergillus strain under any atmospheric conditions. Figures 2 and 3 show the microdilution plates used in MICA susceptibility tests after incubation. The plate incubated in air demonstrates the characteristic slight reduction in growth at the MIC of the isolate. As normally is seen, the exact well which is assigned the MIC is open to debate with the possibility of inter-operator errors in the interpretation. The microdilution plate incubated in 1% O 2 demonstrates a very clear endpoint with only occasional colonies growing on the surface of the liquid in the wells at concentrations higher than the MIC.
Summaries of the in vitro susceptibility tests of Candida are presented in Table 2 .
MICs and MFCs for Candida (both individual species and data combined from all species) of AMB, ITC and MICA demonstrated no statistical differences between incubation conditions. In most MICA demonstrated no trends in either MIC or MFC between incubation conditions. Both the MIC and MFC of MICA were much higher in all conditions for C. parapsilosis and C. guilliermondii.
Atmospheres generated with either anaerobic or microaerophilic gas packs (data not shown) do not replicate the growth patterns seen in 1% or 0.25% oxygen.
Discussion
One aim of antifungal susceptibility testing is to provide data which will guide the clinician treating the patient with information on isolates that is predictive of therapeutic success or failure. It is clear that currently there is a large gap between in vitro and in vivo response to some antifungal agents. Reliable susceptibility data are an essential aid in the selection of therapy for fungal disease. The effectiveness of the treatment of invasive or disseminated disease is at best moderate. This is reflected in the high mortality rates associated with invasive fungal disease even when appropriate treatment (as predicted by in vitro susceptibility) is aggressively administered. 5 For many years, amphotericin B deoxycholate has been the standard treatment for invasive aspergillosis even though responses are suboptimal (less than 40%) in severely immunocompromised patients. 21, 22 The decision to treat with amphotericin B is not always simple as treatment is associated with multiple side effects (even though these may be reduced with the lipid formulations), 23 but if the in vitro susceptibility data are unreliable, this makes the decision even more difficult. It has recently been reported that voriconazole may be an effective alternative to amphotericin B in the primary treatment of invasive aspergillosis 24 but even in this study, survival at 12 weeks was only 71% (with just 21% demonstrating a complete response). It is therefore clear that there is scope for large improvements in the efficacy of treatment in this patient group.
MIC methodologies are designed to predict the in vivo susceptibility of fungi infecting patients. It has previously been demonstrated that MICs can vary depending on the test format and the fungal species tested. 11, 25 Multiple factors have been shown to influence the outcome of fungal MIC measurement including the format (macro-versus micro-dilution), 26,27 culture medium, 28,29 inoculum concentration, 20,30 and temperature of incubation. 31, 32 Methods by comparison with in vivo models have been published for a variety of fungi/antifungal agent combinations including the Aspergillus/itraconazole combination 30, 33, 34 and the Candida/ fluconazole combination. 11, 35 It has so far not been possible to validate a susceptibility test for the Aspergillus/amphotericin B combination using animal models 10,30 but some degree of agreement was possible using correlation with clinical outcome. 36 Correlation of susceptibility results with clinical outcome has been possible with mucosal Candida infection (oropharyngeal thrush and oesophagitis), but is more difficult with disseminated candidiasis or aspergillosis as a result of the complex nature of the disease and poor outcome.
Susceptibility testing of Candida to the echinocandins using an adapted NCCLS M27-A2 protocol appears reliable 37, 38 with clear endpoints in susceptible strains and reduced in vitro susceptibility in resistant strains. Unfortunately, determining the MIC of the echinocandins for Aspergillus is not possible due to the incomplete nature of the inhibition. 39, 40 Therefore a revised interpretation of the MIC to the minimum effective concentration (MEC) has been suggested. 41 The MEC is the point at which there is a transition of growth from a homogeneous hyphal mat to small spherical colonies. 16, 42 a reduction in the in vitro MIC (2-4 fold) of amphotericin B occurs. This would obviously have many advantages as drug delivery to some infected tissues is less than ideal and an increased ratio of tissue drug level to MIC would point to a therapeutic advantage for these drugs. Unfortunately, with amphotericin B we demonstrated no change in the MFC for Aspergillus in hypoxic conditions. It therefore appears that amphotericin is acting more as a fungistatic agent than a fungicidal agent. It would therefore seem good practice in patients with both aspergillosis and neutropenia to continue therapy until the neutropenia is resolved (particularly if the antifungal activity is predominantly fungistatic) but with amphotericin B this is often not possible because of adverse effects. In a recent study comparing treatment of invasive aspergillosis with voriconazole or amphotericin B, 24 amphotericin B therapy was used for a mean duration of only 10 days before therapy was changed; this in many cases would be before the resolution of neutropenia.
Hypoxic conditions did not alter either the MIC or the MFC of micafungin. However, growth of Aspergillus in the presence of micafungin in 1% oxygen was completely inhibited, aside from occasional surface or meniscus growth, which could represent inadequate exposure of individual conidia to the drug. This effect was also seen with caspofungin and anidulafungin (data not shown). So it is possible to assign an MIC with confidence rather than an MEC, using these conditions.
The echinocandins have been shown to be highly effective in treating both primary and refractory aspergillosis even though in vitro their inhibition of Aspergillus is incomplete. We have demonstrated that in conditions modelling hypoxia, the inhibition of hyphal growth by the echinocandins is almost total and is vastly superior to that occurring in air. It is possible that this high-level inhibition also occurs in tissues infected with Aspergillus as a result of the local hypoxic conditions caused by poor oxygen delivery.
